Company Filing History:
Years Active: 2010-2011
Title: **Gerrit Jan Ettema: Innovator in Pharmaceutical Crystallization**
Introduction
Gerrit Jan Ettema, a prominent inventor based in Nijmegen, Netherlands, has made significant contributions to the field of pharmaceuticals. With a focus on innovative methodologies for drug formulation, he holds two patents that reflect his expertise and dedication to advancing healthcare solutions.
Latest Patents
Ettema's latest patents involve advanced formulations of aripiprazole, a medication used in the treatment of various mental health disorders. His patents include "Crystalline aripiprazole solvates" which discusses the utility of alcoholates of aripiprazole as pharmaceuticals and intermediates in the production of aripiprazole Form A or Form B. Additionally, he has patented a process for producing crystalline aripiprazole, specifically Form B, through crystallization from solvents, including 1-propanol, 2-propanol, 1-butanol, ethyl acetate, and acetonitrile, among other combinations.
Career Highlights
Gerrit Jan Ettema currently works for Synthon B.V., a company known for its commitment to developing innovative pharmaceutical solutions. His work not only enhances the efficiency of drug production but also contributes to the accessibility of effective treatments for patients.
Collaborations
In his professional journey, Ettema has collaborated with notable colleagues, including Raymond Westheim and Faysal Kalmoua. These partnerships highlight a collaborative approach to research and innovation within the pharmaceutical industry, fostering an environment where groundbreaking ideas can flourish.
Conclusion
In summary, Gerrit Jan Ettema exemplifies the spirit of innovation in pharmaceuticals. With his two patents and a collaborative work ethic at Synthon B.V., he continues to contribute valuable advancements in drug formulation and production. His work not only demonstrates his expertise but also has the potential to impact healthcare positively, ensuring better treatment options for patients worldwide.